

PKLR Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP7043b**Specification****PKLR Antibody (C-term) Blocking Peptide -
Product Information**Primary Accession [P30613](#)**PKLR Antibody (C-term) Blocking Peptide -
Additional Information****Gene ID** 5313**Other Names**Pyruvate kinase PKLR, Pyruvate kinase 1,
Pyruvate kinase isozymes L/R, R-type/L-type
pyruvate kinase, Red cell/liver pyruvate
kinase, PKLR, PK1, PKL**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP7043b](#) was selected from the C-term region of human PKLR . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**PKLR Antibody (C-term) Blocking Peptide -
Protein Information****Name** PKLR**PKLR Antibody (C-term) Blocking Peptide -
Background**

PKLR is a pyruvate kinase that catalyzes the production of phosphoenolpyruvate from pyruvate and ATP. Defects in this enzyme, due to gene mutations or genetic variations, are the common cause of chronic hereditary nonspherocytic hemolytic anemia (CNSHA or HNSHA).

**PKLR Antibody (C-term) Blocking Peptide -
References**

Wang, H., et al., Diabetes 51(9):2861-2865 (2002).Valentini, G., et al., J. Biol. Chem. 277(26):23807-23814 (2002).Mateu, E., et al., Hum. Genet. 110(6):532-544 (2002).Indo, Y., et al., Hum. Mutat. 18(4):308-318 (2001).Acan, N.L., et al., J. Enzym. Inhib. 16(5):457-464 (2001).

Synonyms PK1, PKL

Function

Plays a key role in glycolysis.

**PKLR Antibody (C-term) Blocking Peptide -
Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)